Mutation analysis of the p73 gene in nonastrocytic brain tumours

ME Alonso1, MJ Bello1, P Gonzalez-Gomez1, J Lomas1, D Arjona1, JM de Campos2, ME Kusak2, JL Sarasa2, A Isla2 and JA Rey1

1Laboratorio de Oncogenética Molecular, Unidad de Investigación, Departamento de Cirugía Experimental, Hospital Universitario La Paz, 28046 Madrid, Spain; 2Departamento de Neurocirugía, Hospital del Río Hortega, 47010 Valladolid, Spain; 3Departamento de Anatomía Patológica, Fundación Jiménez Díaz, 28040 Madrid, Spain; 4Departamento de Neurocirugía, Hospital Universitario La Paz, 28046 Madrid, Spain

Summary

Loss of heterozygosity (LOH) involving the distal chromosome 1p36 region occurs frequently in nonastrocytic brain tumours, but the tumour suppressor gene targeted by this deletion is unknown. p73 is a novel gene that has high sequence homology and similar gene structure to the p53 gene; it has been mapped to 1p36, and may thus represent a candidate for this tumour suppressor gene. To determine whether p73 is involved in nonastrocytic brain tumour development, we analysed 65 tumour samples including 26 oligodendrogliomas, 4 ependymomas, 5 medulloblastomas, 10 meningiomas, 2 meningeal haemangiopericytomas, 2 neurofibrosarcomas, 3 primary lymphomas, 8 schwannomas and 5 metastatic tumours to the brain, for p73 alterations. Characterization of allelic loss at 1p36–p35 showed LOH in about 50% of cases, primarily involving oligodendroglial tumours (22 of 26 cases analysed; 85%) and meningiomas (4 of 10; 40%). PCR-SSCP and direct DNA sequencing of exons 2 to 14 of p73 revealed a missense mutation in one primary lymphoma: a G-to-A transition, with Glu291Lys change. 8 additional cases displayed no tumour-specific alterations, as 3 distinct polymorphic changes were identified: a double polymorphic change of exon 5 was found in one ependymoma and both samples derived from an oligodendroglioma, as follows: a G-to-A transition with C-to-T change at exon 2/+10 position was present in a metastatic tumour. Although both LOH at 1p36 and p73 sequence changes were evidenced in 4 cases, it is difficult to establish a causal role of the p73 variations and nonastrocytic brain tumours development. © 2001 Cancer Research Campaign http://www.bjncancer.com

Keywords: p73 gene; nonastrocytic tumours; LOH 1p36; primary brain lymphoma

p53 is the most frequently mutated tumour suppressor gene identified to date (Hollstein et al, 1991), and Kaghad et al (1997) reported a novel gene, termed p73, that encodes a nuclear protein sharing significant sequence homology with p53, especially in the domains of transcriptional activation, DNA-binding and oligomerization. p73 activates the transcription of p21waf1/cip1, inhibits cell growth, and induces apoptosis (Jost et al, 1997); however, unlike p53, p73 is not induced by exposure of cells to DNA-damaging agents such as UV irradiation (Kaghad et al, 1997).

The chromosomal localization of p73 is proximal to marker D1S468 and distal to marker D1S47, at 1p36.33–p36.32 (Liu et al, 2000). This region is frequently deleted in a variety of human tumours (Mitelman et al, 1997). We previously reported 1p allelic deletions in about 30% of brain tumours (Bello et al, 1995a), with higher frequencies of loss found in oligodendrogliomas and meningiomas, and a lesser degree in neurofibrosarcomas, schwannomas and primary lymphomas. Most of these tumour types display a low frequency of p53 abnormalities, suggesting that other molecular carcinogenic pathways may participate during their progression (Ohgaki et al, 1991).

Human carcinogenesis is believed to be a multistage process involving somatic activation of protooncogenes and inactivation of tumour suppressor genes or DNA repair genes. In brain tumours, some of these genetic alterations have been outlined for astrocytic neoplasms (von Deimling et al, 1995), and recent data on molecular progression of meningioma and oligodendroglioma have emerged (Reifenberger et al, 1994; Bello et al, 1995b; Kraus et al, 1995; Simon et al, 1995; Leone et al, 1999; Smith et al, 1999). Several 1p candidate tumour suppressor genes have been analysed for inactivating mutations in oligodendrogliomas and meningiomas, including hRAD54 and CDKN2C genes. There is nonetheless insufficient evidence to consider these genes as candidate tumour suppressor genes in these nonastrocytic neoplasms (Huseman et al, 1999; Mendiola et al, 1999; Bello et al, 2000b).

To evaluate possible p73 involvement in the pathogenesis of nonastrocytic brain tumours, we analysed 65 tumour samples for mutations of the p73 gene, and loss of heterozygosity at the 1p36 region. Contrary to our predictions, we found that the p73 mutation was infrequent in these tumour types.

MATERIALS AND METHODS

Tissue samples and DNA preparation

Normal tissues and tumour biopsies from 65 patients with nonastrocytic brain tumours were collected during surgical procedures and frozen immediately at –80°C until use. All samples were classified by histologic examination and graded according to WHO guidelines (Kleihues et al, 1993). The group of 65 tumours

Received 18 January 2001
Revised 26 March 2001
Accepted 27 March 2001
Correspondence to: JA Rey

http://www.bjncancer.com
consisted of 26 oligodendrogliomas, 4 ependymomas, 5 medulloblastomas, 10 meningiomas, 2 meningeval haemangiopericytomas, 3 primary lymphomas, 2 neurofibrosarcomas, 8 schwannomas and 5 metastatic tumours to the brain. The tumour cell content was estimated by histologic examination to be approximately 75–80%.

DNA was prepared from frozen tissues and blood samples using standard methods, as described previously (Rey et al, 1992).

**Loss of heterozygosity at 1p36–p35**

To verify LOH at 1p36–p35, restriction fragment length polymorphism (RFLP) and microsatellite analyses were performed using the methods of Leone et al (1999), and the allelic constitution of the following 1p markers was determined: D1Z2, D1S80, D1S76, and D1S77, located at 1p36.33; D1S468, and D1S234, at 1p36.32; D1S199, at 1p36.12, and D1S214, at 1p35.3. The plasmids and/or oligonucleotide primers used to detect these markers have been described previously (Bello et al, 2000a), and were obtained from the American Type Culture Collection (Manassas, VA) or GENSET, SA (France). Restriction endonuclease digestion, agarose gel electrophoresis, southern blotting, 32P-labelling of DNA probes, hybridization and autoradiography were performed as described (Rey et al, 1992). Cytosine adenine repeat polymorphisms were analysed using polymerase chain reaction in standard conditions; the alleles were resolved in 6% polyacrylamide gels and then silver stained (Bender et al, 1994). Scanning densitometry was performed to determine the allelic status of markers studied by RFLP/autoradiography or PCR/SSCP/silver stain as described in detail elsewhere (Bello et al, 2000a). Loss of heterozygosity was defined as greater than 75% reduction in band intensity relative to the non-tumour control.

**SSCP analysis and direct sequencing of p73 gene**

Genomic PCR amplification of coding exons 2–14 of the p73 gene and their splice site junction sequences were performed using the primers described by Yoshikawa et al (1999) (purchased from GENSET). PCR conditions were 35 cycles of 94°C for 30 s, 55–68°C for 30 s, and 72°C for 90 s, with a final extension of 7 min at 72°C. The PCR products were loaded onto 6–12% nondeaturing polyacrylamide gels (with or without 10% glycerol), electrophoresed and silver stained as above. Samples displaying an altered PCR-SSCP pattern were reamplified by PCR, with the same set of primers, and the PCR products were sequenced using the ABI PRISM Big Dye Terminator Cycle Sequencing Kit (Perkin Elmer, Alameda, CA). Each amplicon was sequenced bidirectionally.

**RESULTS**

Allelic loss at the p73 region (1p36.33–p36.32) could be unambiguously determined in 33 of the 65 tumour samples (50%), corresponding to 22 oligodendrogliomas, 1 ependymoma, 4 meningiomas, 1 lymphoma, 1 neurofibrosarcoma, 2 schwannomas and 2 metastatic tumours to the brain. Detailed data on the allelic constitution have been partially reported previously (Bello et al, 1999a, 1999b, unpublished data).

The genomic region from exons 2 to 14, which cover the entire coding frame of p73, was searched for mutations in all 65 tumours. We found a single tumour (primary lymphoma) characterised by a missense mutation, a G-to-A change at nucleotide 871 (exon 8), that is, a Glu291Lys (GAG to AAG) change (Figure 1). 2 silent mutations (or polymorphisms) were identified in both samples corresponding to grade II and grade III of an oligodendroglioma patient (case K-9). The first was a G-to-A transition at nucleotide 438 (exon 5), which does not result in aminoacid change (CCG to CCA; no change Pro 146). The second exon 5 polymorphism detected in both samples was a C-to-T change at nucleotide 612, with no change of Asn 204. Both exon 5 polymorphic variations were also detected in an ependymoma (case K-30). 5 additional tumours displayed nucleotide changes occurring in the introns. One delG at the downstream region of exon 3 (+12) position was identified in 2 oligodendrogliomas, 1 ependymoma and 1 meningioma. Finally, a C-to-T change at the exon 2(+10) position was identified in one brain metastatic lesion from a lung carcinoma. A summary of the nucleotide changes detected in all 9 tumours is shown in Table 1.

Allele loss at the 1p36 region was identified in 4 tumours with p73 sequence changes; these corresponded to 3 samples of oligodendroglioma and to the brain metastatic lesion from a lung carcinoma. Allelic retention was evidenced in the case with missense mutation (tumour K-42).

**DISCUSSION**

Chromosomal region 1p36 is frequently deleted in human cancer (Mitelman et al, 1997), and considered to harbour up to 3 tumour suppressor genes relevant to the carcinogenesis of a variety of neoplasms (Vergsteeg et al, 1995). We previously performed deletion mapping analysis of 1p in a broad series of 236 tumours of the nervous system, including all major histologic subtypes (Bello et al, 1995a), and determined that an average of 30% of cases displayed allelic losses at that chromosomal region. We then performed high-resolution deletion mapping analyses (composite average resolution of 4.04 cM) in nonastrocytic brain tumours and allelic imbalance at 1p36 was identified in 28% of meningiomas and 74% of tumours with a major oligodendrogliial component (Bello et al, 2000a, b). At a lower frequency, 1p36 deletions were
also identified in schwannomas, neurofibrosarcomas and primary lymphomas (Bello et al, 1995a, and unpublished data), and similar deletions are evidenced in the present report. These data concur with previous findings in other tumour types, prompting us to analyse molecular abnormalities of candidate genes at 1p36.

p73, a p53-related gene, has been located in this critical region (Kaghad et al, 1997; Liu et al, 2000) and may be the putative tumour suppressor gene involved in carcinogenesis in a variety of neoplasms, including nonastrocytic brain tumours. In this study we screened 65 nonastrocytic brain tumours for p73 gene mutations, but identified only a single case with a missense mutation, Glu291Lys in a primary lymphoma which nevertheless retained the intact allele, shown by the retention of heterozygosity at the 1p36 region. We also detected 8 additional cases displaying polymorphic changes, as they were also present in the corresponding constitutional DNA, but not all evidenced LOH at 1p36.

Taken together, our findings do not support a major role for p73 as a tumour suppressor gene in nonastrocytic brain tumours. Similar findings were previously reported for oligodendrogliomas (Mai et al, 1998; Tsujimoto et al, 2000), as several polymorphic nucleotide variations, but no somatic mutations that caused amino acid changes were detected. High resolution deletion mapping analysis of 1p in meningioma and oligodendroglioma has demonstrated that more than one tumour suppressor gene from this genomic region might be involved. We previously performed mutational studies of the hRAD54 gene (located at 1p32) in those nonastrocytic brain tumours, but no mutational changes were detected (Mendiola et al, 1999; Bello et al, 2000b). Abnormalities of the CKRN2C gene are likewise rarely found in oligodendrogliomas with 1p deletion (Huseman et al, 1999) and, the target gene of these highly frequent 1p deletions, characteristic of the brain neoplasms, thus remains to be identified. As far as we know, mutational analysis of the p73 gene has been performed in several human cancers (Leverero et al, 2000), but no data are available for the other nonastrocytic brain tumour types we studied. In accordance with our findings, mutations of the gene are rarely found. In this respect, van Gele et al (2000) described the finding of a sporadic p73 NH2-terminal located missense mutation in one of 10 Merkel cell carcinomas studied. Ichimiya et al (1999) found one somatic and one germ-line mutation in a series of 140 neuroblastomas, and Han et al (1999) described a somatic missense mutation at codon 269 in a primary lymphoma which nevertheless retained the intact allele, shown by the retention of heterozygosity at the 1p36 region. We also detected 8 additional cases displaying polymorphic changes, as they were also present in the corresponding constitutional DNA, but not all evidenced LOH at 1p36.

Table 1

| Sample | Tumour type | Exon/intron | Nucleotide change | AA change | LOH 1p36 |
|--------|-------------|-------------|-------------------|-----------|----------|
| K-9 T1 | O           | 5           | 3G>C,A/6T>C>T    | Pro146Pro/Asn204Asn | +        |
| K-9 T2 | AO          | 5           | 3G>C,A/6T>C>T    | Pro146Pro/Asn204Asn | +        |
| K-13   | O           | 3,+12       | delG             | –         | –        |
| K-15   | O           | 3,+12       | delG             | –         | –        |
| K-30   | E           | 5           | 3G>C,A/6T>C>T    | Pro146Pro/Asn204Asn | –        |
| K-32   | E           | 3,+12       | delG             | –         | –        |
| K-42   | L           | 8           | 3G>C,A           | Glu291Lys | –        |
| K-43   | M           | 3,+12       | delG             | –         | –        |
| K-59   | Met-LungCa  | 2,+10       | C>T              | –         | +        |

Tumour type: O = oligodendroglioma; AO = anaplastic oligodendroglioma; E = ependymoma; L = primary brain lymphoma; M = meningioma; Met-Lung Ca = lung carcinoma metastatic to the brain.

In conclusion, the present study clearly demonstrates frequent allelic loss at 1p36, where the p73 gene is located, in nonastrocytic brain tumours. We describe the finding of a p73 missense mutation.
that might inactivate the gene, in a primary intracranial lymphoma, together with the identification of 3 previously reported polymorphic changes. Nevertheless, p73 does not seem to behave as a classical 'two-hit' tumour suppressor gene in nonastrocytic brain tumours, as our study provides evidence that mutation of this gene is unlikely to play a major role in the pathogenesis of these nervous system tumours, other than brain primary lymphomas. The high incidence of 1p36 deletions clearly provides evidence for a tumour suppressor gene located here, whose inactivation would be a critical step in promoting tumour growth in these neoplasms.

ACKNOWLEDGEMENTS

Support for this work was provided by grant 00/0331 from FIS, Ministerio de Sanidad. MEA, is supported by a fellowship from Comunidad de Madrid.

REFERENCES

Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, Vaquero J, Sarasá JL, García-Miguel P, Quezán A, Hernandez-Moneo JL, Pestaña A and Rey JA (1995a) Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 83: 160–164
Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasá JL, Pestaña A and Rey JA (1995b) Allelic loss at 1p and 1q frequently occurs in association and may represent early oncogenic events in oligodendrogliomas. Int J Cancer 60: 207–210
Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasá JL and Rey JA (2000a) High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet 120: 30–36
Bello MJ, de Campos JM, Vaquero J, Ruiz-Barnes P, Kusak ME, Sarasá JL and Rey JA (2000b) hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas. Cancer Genet Cytogenet 116: 142–147
Bender B, Wiestler OD and von Deimling A (1994) A device for processing large DNA samples. Technical report. Institute of Neuroanatomy and Neurobiology. Technical report. The Technical University of Munich, Munich, Germany
Corn PG, Kueberlitz SJ, Noe Vanessel MM, Esteller M, Compitello N, Baylin SB and Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5' CpG island methylation. Cancer Res 59: 3352–3356
De Laurenzi V, Catani MV, Terrinoni A, Corazza M, Melino G, Costanzo A, Gog J, Melino G and Wang JY (1999) Structure, function and regulation of p63 and p73. Cell Death Differentiation 6: 1146–1153
Leverro M, De Laurenzi V, Costanzo A, Gog J, Melino G and Wang JY (2000) The p33/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113: 1661–1670
Liss NY, Davis PK, Irwin M, Kaatin WD and Dowdy SF (2000) A common EZF1 and p73 pathway mediates cell death induced by TCR activation. Nature 407: 642–645
Liu W, Mai J, Yozomizo A, Qian C, Tindall DJ, Smith DI and Thibodeau SN (2000) Differential expression and allelotyping of the p73 gene in neuroblastoma. Int J Oncol 16: 181–185
Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R, Smith DI and Liu W (1998) Genetic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1p arm deletions. Genomics 51: 359–363
Matsunaga Y, Makashita S, Yoshimoto T, Sekiya T and Hayashi K (1991) Detection of p53 gene mutations in human tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6: 1313–1318
Mendola M, Bello MJ, Alonso J, Leone PE, Vaquero J, Sarasá JL, Kusak ME, de Campos JM, Pestaña A and Rey JA (1999) Search for mutations of the hRAD54 gene in sporadic meningioma with deletion at 1p32. Mol Carcinogenesis 24: 300–304
Miettinen F, Mertens F and Johansen B (1997) A breakpoint map of recurrent rearrangements in human neoplasia. Nature Genetics 15: 417–474
Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T and Takahashi T (1998) Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58: 1380–1383
Ohgaki H, Ebih RB, Wiestler OD, Yasargil MG, Newcomb EW and Kleihues P (1991) p53 mutations in nonastrocytic brain tumors. Cancer Res 51: 6202–6205
Peng C-Y, Tsai C-L, Yeh C-T, Hung S-P, Chen M-F, Chen T-C, Chu C-M and Liaw Y-F (2000) Genetic alterations of p73 are infrequent but may occur in early stage hepatocellular carcinoma. Anticancer Res 20: 1487–1492
Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W and Collins VP (1994) Molecular genetic analysis of oligodendrogliomas shows preferential allelic deletions on 19q and 1p. Am J Pathol 145: 1175–1180
Rey JA, Bello MJ, Jimenez-Lara A, Vaquero J, Kusak ME, de Campos JM, Sarasá JL and Pestaña A (1992) Loss of heterozygosity for mitotic markers on 22q in human gliomas. Int J Cancer 51: 703–706
Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM and Menon AG (1995) Allelic losses on chromosome 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 55: 4696–4701
Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel M, D’Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW and Jenkins RB (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18: 4144–4152
Takahashi T, Ichimura S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Takahashi T and Takahashi T (1998) Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58: 1380–1383
Van Gele M, Mackghi M, Leonard JH, Van Roy N, Naeyaert JM, Geerts ML, Van Belle S, Coquyt V, Bridge J, Sciot R, De Wolf-Peeters C, De Paepe A and Caput

© 2001 Cancer Research Campaign
British Journal of Cancer (2001) 85(2), 204–208
D and Speleman F (2000) Mutation analysis of p73 and TP53 in Merkel cell carcinoma. Br J Cancer 82: 823–826
Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voute PA, Delatre O, Laureys G, Van Roy N and Speleman F (1995) 1p36: Every subband a suppressor? Eur J Cancer 31A: 538–541
von Deimling A, Louis DN and Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15: 328–338
White E and Prives C (1999) DNA damage enables p73. Nature 399: 734–735
Yang A, Kaghad M, Wang Y, Gillet E, Fleming MD, Dotsch V, Andrews NC, Caput D and McKeon F (1998) p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305–316
Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F and Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404: 99–103
Yokozaki H, Shitara Y, Fujimoto JY, Hiyama T, Yasui W and Tahara E (1999) Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer 83: 192–196
Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K and Harris CC (1999) Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18: 3415–3421